What is the efficacy of sunitinib to treat renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

In a phase 3 study in 750 patients with previously untreated metastatic RCC progression-free survival was longer and response rates were higher in patients who received sunitinib than in those receiving interferon alfa (IFN-alfa). [30] In final survival analyses, the median overall survival (26.4 mo) and the objective response rate (47%) was greater in the sunitinib group than in the IFN-alfa group (21.8 mo and 12%, respectively). [31]

An expanded-access trial that provided sunitinib on a compassionate-use basis to 4564 trial-ineligible patients with RCC from countries where regulatory approval had not been granted suggested that the safety of sunitinib in these patients was manageable and its efficacy was encouraging, particularly in subgroups associated with poor prognosis (eg, those with brain metastases, low performance status, non–clear cell disease, and elderly patients). [32] Median progression-free survival was 10.9 months and overall survival was 18.4 months (17.4-19.2 mo).


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!